Cargando…

Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation

Hypoxia is a central problem in tumor treatment because hypoxic cells are less sensitive to chemo- and radiotherapy than normoxic cells. Radioresistance of hypoxic tumor cells is due to reduced sensitivity towards low Linear Energy Transfer (LET) radiation. High LET α-emitters are thought to eradica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wulbrand, Christian, Seidl, Christof, Gaertner, Florian C., Bruchertseifer, Frank, Morgenstern, Alfred, Essler, Markus, Senekowitsch-Schmidtke, Reingard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665541/ https://www.ncbi.nlm.nih.gov/pubmed/23724085 http://dx.doi.org/10.1371/journal.pone.0064730

Ejemplares similares

Diverse metabolic response of cancer cells treated with a (213)Bi-anti-EGFR-immunoconjugate
por: Feuerecker, Benedikt, et al.
Publicado: (2021)

Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide (213)Bi-DTPA-[F3](2) into the Nucleus of Tumor Cells
por: Drecoll, Enken, et al.
Publicado: (2009)

α-Radioimmunotherapy with (213)Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
por: Teiluf, Katharina, et al.
Publicado: (2014)

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics
por: Šimeček, Jakub, et al.
Publicado: (2018)

Assessment of (213)Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-(13)C]pyruvate and [(18)F]FDG
por: Feuerecker, Benedikt, et al.
Publicado: (2019)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

First‐Generation Bispidine Chelators for (213)Bi(III) Radiopharmaceutical Applications
por: Bruchertseifer, Frank, et al.
Publicado: (2020)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
por: Chan, Ho Sze, et al.
Publicado: (2016)

Long-Term Toxicity of (213)Bi-Labelled BSA in Mice
por: Dorso, Laëtitia, et al.
Publicado: (2016)

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate
por: Chan, Ho Sze, et al.
Publicado: (2016)

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue
por: Krolicki, Leszek, et al.
Publicado: (2018)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis
por: Derrien, Aurélie, et al.
Publicado: (2015)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
por: Kratochwil, C., et al.
Publicado: (2014)

Studies of $\alpha$-spectra in $^{221}Fr, ^{217}At, ^{213}Bi$ and $^{213}Po$ decays
por: Chumin, V G, et al.
Publicado: (1997)

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the (213)Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
por: Gustafsson-Lutz, Anna, et al.
Publicado: (2017)

Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter (213)Bi
por: Cytryniak, Adrianna, et al.
Publicado: (2022)

Therapeutic Performance Evaluation of (213)Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([(213)Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology
por: Képes, Zita, et al.
Publicado: (2023)

Level structure in $^{213}Bi$
por: Chumin, V G, et al.
Publicado: (1996)

Targeted alpha therapy for glioblastoma
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene
por: Grünwald, Geoffrey K, et al.
Publicado: (2013)

Dual‐Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy
por: Wurzer, Alexander, et al.
Publicado: (2017)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer
por: Yoshida, Takahiro, et al.
Publicado: (2016)

Radioimmunotherapy of micrometastases in lung with vascular targeted(213)Bi
por: Kennel, S J, et al.
Publicado: (1999)

Functionalized NaA nanozeolites labeled with (224,225)Ra for targeted alpha therapy
por: Piotrowska, Agata, et al.
Publicado: (2013)

Global experience with PSMA-based alpha therapy in prostate cancer
por: Sathekge, Mike M., et al.
Publicado: (2021)

Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives
por: Mercatelli, Daniele, et al.
Publicado: (2018)

Gamma counting protocols for the accurate quantification of (225)Ac and (213)Bi without the need for a secular equilibrium between parent and gamma-emitting daughter
por: Castillo Seoane, Dayana, et al.
Publicado: (2022)

Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.
por: King, D. J., et al.
Publicado: (1995)

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model
por: Fichou, Nolwenn, et al.
Publicado: (2015)

EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy
por: Ye, Zixuan, et al.
Publicado: (2021)

A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling
por: Ermolaev, Stanislav, et al.
Publicado: (2021)

Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
por: Kondo, Yasuyuki, et al.
Publicado: (1995)

Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells
por: Khandelwal, Soni, et al.
Publicado: (2018)

Functionalized TiO(2) nanoparticles labelled with (225)Ac for targeted alpha radionuclide therapy
por: Cędrowska, Edyta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3rv5gcvtctqqh6pghsjeau5aq5